English version  
Injection Accueil Produits Recherche  et  Dev./F.A.Q Nouvelles À propos de nous Contactez-nous

Dr. Francis Bellido named Vice-President and Chief Strategy Officer of Medical International Technology Inc.
Tuesday, February 9th 2010

DENVER, CO, Feb. 9 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.OB) http://www.mitneedlefree.com/ MIT is pleased to announce the nomination of Dr. Francis Bellido, PhD, MBA, as the 4th member to join the newly-formed Advisory Board. Mr. Bellido will also hold the position of Vice-President and Chief Strategy Officer.

Dr. Francis Bellido has more than 25 years of experience in the Biosciences and Financial industries. He has held several top executive positions in both small and large companies. He was President and Chief Operating Officer at Supratek Pharma, a pharmaceutical company specializing in the development of cancer drugs. While President and Chief Executive Officer of SGF-Santé he managed a $500M health science investment portfolio. Dr. Bellido has also held several executive positions with Eli Lily in the United States and Europe including Strategic Asset Director, Global Business Unit Manager and Head of Regulatory Affairs. Dr. Bellido also received a Masters degree in Pharmaceutical Sciences and a Ph.D. in Medical Microbiology from the University of Geneva in Switzerland. He received his MBA from the University of Montréal. He has held the position of Invited Professor at the School of Management of the University of Québec in Montréal.

The nomination and acceptance by Dr. Francis Bellido to join MIT's Advisory Board and his assuming the position of Vice-President and Chief Strategy Officer of Medical International Technology Inc. will strengthen MIT's management team. The addition of Dr. Bellido will also enrich negotiation opportunities with Medical and Pharmaceutical companies and help MIT achieve its goal to partner with multinational corporations. MIT President & CEO, Mr. Karim Menassa, believes that this is a very important and positive step for the immediate and future success of the company.

Medical International Technology Inc. is proud to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.

About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.

Medical International Technology, Inc.

Poland Japan Taiwan Korea Finland Greece Czech Republic Sweden Denmark France Canada Montana